|
PERMAX
Permax is used to treat Parkinson's disease, a progressive neurological condition affecting movements such as walking, talking, and writing. Permax has been approved for treatment of Parkinson’s since 1989. Since its approval, Permax has been prescribed to more than 500,000 people for the control of tremors and restless leg syndrome.
Cardiologists at the Mayo Clinic have found valvular heart disease in three clinic patients who had been taking Permax for several years. All three patients had severe tricuspid regurgitation or "leakage" with regurgitation in the aortic and/or mitral valves. The valvular heart disease found in these patients is similar to the damage found in patients who took the Fen-Phen/Redux diet drugs.
Later tests performed by researchers from the University of Texas Southwest Medical Center found a threefold increased risk of heart valve damage among patients who used Permax.
Symptoms of valvular heart disease may include shortness of breath, chest pain, palpitations, fatigue, and swelling of the feet and ankles. Some patients with valvular heat disease have no symptoms at all. An echocardiogram must be done to determine whether an individual suffers from abnormal valvular regurgitation.
PERMAX NEWS
Eli Lilly Canada Inc., in collaboration with Health Canada, announces that sales of Permax will cease in Canada as of August 30, 2007. (Aug-13-07) DOCGUIDE: PERMAX
The State Food and Drug Administration (SFDA) announced that Permax, a drug taken for Parkinson's disease, will be gradually removed from the Chinese market because of the risk of heart damage.
(Jun-26-07) PERMAX: China View
European researchers have found Permax increases the risk of cardiac-valve regurgitation. (Jan-04-07) PERMAX: MedPage Today
|
 |
|